Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07766369 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

StatusRecruiting
PhasePhase 1
SponsorEisai Inc.
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Eligibility criteria expanded, about 23 words · Site details revised Show 2 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Biogen
92 trials monitored
See 7 trials at risk
The primary purpose of this study is to assess potential drug-drug interactions of E2086 when coadministered orally with Itraconazole, Carbamazepine, Midazolam, Dextromethorphan, Bupropion, or Combined Oral Contraceptives in Healthy Participants
Trial Details
NCT Number NCT07766369
Lead Sponsor Eisai Inc.
Conditions Healthy Volunteers
Enrollment 93 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov